Skip to main content

EAACI 2025 Sanofi | Regeneron | Jun 13, 2025 - Jun 16, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1
  • Chronic rhinosinusitis with nasal polyps

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease characterized, when uncontrolled, by bilateral nasal polyps, congestion, and impaired sense of smell, that is associated with persistent symptoms and poor quality of life.

  • Asthma

    Asthma is predominately a chronic type 2 inflammatory disease. When uncontrolled, asthma is characterized by impaired lung function, severe exacerbations, recurrent symptoms, and poor quality of life.

  • Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Chronic Obstructive Pulmonary Disease

  • Eosinophilic Esophagitis

    Eosinophilic Esophagitis (EoE) is a chronic type 2 inflammatory disease characterized by specific histologic changes, dysphagia, and poor quality of life due to esophageal scarring and narrowing.